Ruxolitinib Ameliorates Airway Hyperresponsiveness and Lung Inflammation in a Corticosteroid-Resistant Murine Model of Severe Asthma is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5K22CA18814802, 5R00HL12107305, R25-HL108864
NCI NIH HHS
Grant: K22 CA188149
NHLBI NIH HHS
Grant: R25 HL108864
NHLBI NIH HHS
Grant: R00 HL121073
National Institutes of Health
Grant: 2R25HL108864-06A1
Research Education Program to Increase Diversity in Health-Related Research (REPID program)
FWCI
1.82
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Exogenous IL-25 ameliorates airway neutrophilia via suppressing macrophage M1 polarization and the expression of IL-12 and IL-23 in asthma
Additional file 1 of Exogenous IL-25 ameliorates airway neutrophilia via suppressing macrophage M1 polarization and the expression of IL-12 and IL-23 in asthma